Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria

[1]  Andrea P. Madden,et al.  Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients , 2022, JIMD reports.

[2]  George Bou-Gharios,et al.  Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria , 2022, Molecular genetics and metabolism reports.

[3]  M. Bagliani,et al.  Drivers of Protein Consumption: A Cross-Country Analysis , 2021, Sustainability.

[4]  L. Ranganath,et al.  Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature , 2021, JIMD reports.

[5]  L. Ranganath,et al.  Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2‐dioxygenase deficiency in the liver is responsible for homogentisic acid‐derived ochronotic pigmentation , 2020, JIMD reports.

[6]  C. Ficicioglu,et al.  Disorders of phenylalanine and tyrosine metabolism , 2020, Translational Science of Rare Diseases.

[7]  N. Deutz,et al.  Nitisinone causes acquired tyrosinosis in alkaptonuria , 2020, Journal of inherited metabolic disease.

[8]  J. Jarvis,et al.  Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria , 2020, Journal of inherited metabolic disease.

[9]  A. Milan,et al.  Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria , 2019, Scientific Reports.

[10]  A. Milan,et al.  Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. , 2018, Molecular genetics and metabolism.

[11]  F. Aubin,et al.  Richner-Hanhart syndrome (tyrosinemia type II). , 2017, Cutis.

[12]  T. Zubarioglu,et al.  Nitisinone: A review , 2017 .

[13]  F. Eyskens,et al.  Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls , 2016, Orphanet Journal of Rare Diseases.

[14]  L. Ranganath,et al.  Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects , 2015, Clinical chemistry and laboratory medicine.

[15]  Andrea Zatkova,et al.  Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte , 2014, Annals of the rheumatic diseases.

[16]  H. Aiking.  Protein production: planet, profit, plus people? , 2014, The American journal of clinical nutrition.

[17]  J. Troendle,et al.  A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. , 2011, Molecular genetics and metabolism.

[18]  I. D. de Boer,et al.  Urinary Creatinine Excretion Rate and Mortality in Persons With Coronary Artery Disease: The Heart and Soul Study , 2010, Circulation.

[19]  R. Gans,et al.  Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. , 2009, Atherosclerosis.

[20]  M. Ichinose,et al.  Estimation of protein intake using urinary urea nitrogen in patients with early-stage liver cirrhosis , 2007, Hepatology international.

[21]  R. Ball,et al.  Aromatic amino acid requirements in healthy human subjects. , 2007, The Journal of nutrition.

[22]  William A Gahl,et al.  Natural history of alkaptonuria. , 2002, The New England journal of medicine.

[23]  E. Lock,et al.  Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. , 1996, Toxicology and applied pharmacology.

[24]  D. Gripois,et al.  Tyrosine content, influx and accumulation rate, and catecholamine biosynthesis measured in vivo, in the central nervous system and in peripheral organs of the young rat. Influence of neonatal hypo- and hyperthyroidism. , 1989, Archives internationales de physiologie et de biochimie.

[25]  M. Petersen,et al.  Two New Enzymes of Rosmarinic Acid Biosynthesis from Cell Cultures of Coleus blumei: Hydroxyphenylpyruvate Reductase and Rosmarinic Acid Synthase , 1988 .

[26]  B. Madsen,et al.  Linear kinetic model to estimate protein synthesis rate after [14C]tyrosine infusion in dogs , 1977, FEBS letters.

[27]  G. Becker,et al.  A Report of Four Cases and a Review of the Literature , 1974, The Annals of otology, rhinology, and laryngology.

[28]  A. Harper,et al.  Effect of tyrosine and threonine on free amino acids in plasma, liver, muscle, and eye in the rat. , 1966, The Journal of nutrition.

[29]  J. J. Bunim,et al.  Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: Review of world literature (1584–1962) , 1963 .

[30]  A. Milan,et al.  ANNALS EXPRESS: Alkaptonuria - many questions answered, further challenges beckon. , 2019, Annals of clinical biochemistry.

[31]  H. Woodrow,et al.  : A Review of the , 2018 .

[32]  W. Nyhan,et al.  Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria. , 2015, JIMD reports.

[33]  Digital Library Adoption and the Technology Acceptance Model: A Cross-Country Analysis , 2010, Electron. J. Inf. Syst. Dev. Ctries..

[34]  P. Deurenberg,et al.  Validity of predicted total body water and extracellular water using multifrequency bioelectrical impedance in an Ethiopian population. , 1995, Annals of nutrition & metabolism.

[35]  W. Mitch,et al.  A method for estimating nitrogen intake of patients with chronic renal failure. , 1985, Kidney international.